Physician profile
Allison Elizabeth Patrick
NPI 1164263299
$1,056.96
in general payments reported to CMS, 2019-2025
16 companies · $782 in 2025
The $782 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $275 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $298.82 | 2024-2025 | |
| Glaxosmithkline, LLC. | $153.48 | 2025 | Benlysta |
| Janssen Biotech, INC. | $143.71 | 2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $114.14 | 2024-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $46.44 | 2024-2025 | Strensiq |
| Amgen INC. | $43.79 | 2025 | Krystexxa |
| Sobi, INC | $39.56 | 2024-2025 | |
| Abiomed | $36.34 | 2024 | Impella |
| Ani Pharmaceuticals, INC. | $34.54 | 2024 | Purified Cortrophin Gel |
| Organon LLC | $27.23 | 2024 | |
| Tersera Therapeutics LLC | $25.99 | 2025 | Quzyttir |
| Ucb, INC. | $21.74 | 2025 | Bimzelx |
| Aurinia Pharma U.S., INC. | $19.28 | 2025 | Lupkynis |
| Scilex Pharmaceuticals INC. | $17.97 | 2024 | |
| Mallinckrodt Hospital Products INC. | $17.40 | 2025 | Acthar |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.